Agilent Technologies
Official SEC filings
Source: SEC EDGAR. Latest available cached filings; filing date is not the financial period end. Index checked: 2026-11-22 04:43 UTC.
| Form | Filed | Original document |
|---|---|---|
| 8-K | 2026-11-20 | Read on SEC.gov |
| 8-K | 2026-09-08 | Read on SEC.gov |
| 10-Q | 2026-09-01 | Read on SEC.gov |
| 8-K | 2026-08-26 | Read on SEC.gov |
| 8-K | 2026-06-25 | Read on SEC.gov |
| 10-Q | 2026-06-01 | Read on SEC.gov |
| 8-K | 2026-05-27 | Read on SEC.gov |
| 8-K | 2026-05-04 | Read on SEC.gov |
SEC annual financial snapshot
Standard US-GAAP facts in 10-K filings, USD. Income and cash flow cover the annual period; balance-sheet amounts are as of period end. These are not quarterly or TTM figures. Latest available filed values may include restatements; reporting periods can differ from other providers. Checked: 2026-11-21 16:51 UTC.
| Metric | USD | Basis | Period end | Filed | Source |
|---|---|---|---|---|---|
| Revenue | $6.95B | Annual | 2025-10-31 | 2025-12-22 | 10-K |
| Net income | $1.30B | Annual | 2025-10-31 | 2025-12-22 | 10-K |
| Operating cash flow | $1.56B | Annual | 2025-10-31 | 2025-12-22 | 10-K |
| Total assets | $12.73B | As of | 2025-10-31 | 2025-12-22 | 10-K |
| Total liabilities | $5.99B | As of | 2025-10-31 | 2025-12-22 | 10-K |
| Stockholders’ equity | $6.74B | As of | 2025-10-31 | 2025-12-22 | 10-K |
| Cash and cash equivalents | $1.79B | As of | 2025-10-31 | 2025-12-22 | 10-K |
✦ Quant Financial Health how this is computed
- Altman Z-Score is 6.11, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
✦ Quant Revenue Concentration how this is computed
- Agilent CrossLab is the largest reported line at 41.85% of revenue, across 3 reported segments.
- No single line clears half of revenue; Life Sciences and Diagnostics Markets is next at 39.72%, spreading the business across more than one real driver.
Revenue annual, last 8 years
Latest year +6.73% YoY
Margins
- Gross margin
- 52.43%
- Operating margin
- 21.29%
- Net margin
- 18.75%
Key ratios & quality
- Enterprise valuei
- 49.60B
- PEG ratioi
- 26.13
- Altman Z-Scorei
- 6.11
PEG uses trailing P/E against the 3-year net income growth rate (1.29%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.91B | 5.16B | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | 6.95B |
| Gross profit | 2.68B | 2.81B | 2.84B | 3.41B | 3.72B | 3.47B | 3.54B | 3.64B |
| Selling & admin expenses | 1.39B | 1.46B | 1.50B | 1.62B | 1.64B | 1.63B | 1.57B | 1.71B |
| Research & development | 387.00M | 404.00M | 495.00M | 441.00M | 467.00M | 481.00M | 479.00M | 455.00M |
| Operating profit | 904.00M | 941.00M | 846.00M | 1.35B | 1.62B | 1.35B | 1.49B | 1.48B |
| Pretax profit | 946.00M | 919.00M | 842.00M | 1.36B | 1.50B | 1.34B | 1.52B | 1.44B |
| Tax | 630.00M | -152.00M | 123.00M | 150.00M | 250.00M | 99.00M | 232.00M | 132.00M |
| Net profit | 316.00M | 1.07B | 719.00M | 1.21B | 1.25B | 1.24B | 1.29B | 1.30B |
| Basic EPS | 1 | 3 | 2 | 4 | 4 | 4 | 4 | 5 |
| Diluted EPS | 0.97 | 3.37 | 2.30 | 3.94 | 4.18 | 4.19 | 4.43 | 4.57 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 1.67B | 1.74B | 1.86B | 1.80B | 1.84B | 1.88B |
| Gross profit | 866.00M | 888.00M | 990.00M | 946.00M | 990.00M | 1.04B |
| Selling & admin expenses | 454.00M | 417.00M | 428.00M | 476.00M | 465.00M | 475.00M |
| Research & development | 112.00M | 111.00M | 119.00M | 117.00M | 126.00M | 123.00M |
| Operating profit | 300.00M | 360.00M | 443.00M | 353.00M | 399.00M | 444.00M |
| Pretax profit | 260.00M | 366.00M | 442.00M | 364.00M | 408.00M | 444.00M |
| Tax | 45.00M | 30.00M | 8.00M | 59.00M | 69.00M | 82.00M |
| Net profit | 215.00M | 336.00M | 434.00M | 305.00M | 339.00M | 362.00M |
| Basic EPS | 1 | 1 | 2 | 1 | 1 | 1 |
| Diluted EPS | 0.75 | 1.18 | 1.53 | 1.07 | 1.20 | 1.28 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.85B | 3.19B | 3.42B | 3.80B | 3.78B | 4.19B | 3.96B | 4.59B |
| Cash & ST investments | 2.25B | 1.38B | 1.44B | 1.58B | 1.05B | 1.59B | 1.33B | 1.79B |
| Inventory | 638.00M | 679.00M | 720.00M | 830.00M | 1.04B | 1.03B | 972.00M | 1.03B |
| Total assets | 8.54B | 9.45B | 9.63B | 10.71B | 10.53B | 10.76B | 11.85B | 12.73B |
| Total current liabilities | 1.17B | 2.08B | 1.47B | 1.71B | 1.86B | 1.60B | 1.90B | 2.35B |
| Short-term debt | -- | 616.00M | 75.00M | -- | 36.00M | -- | 45.00M | 304.00M |
| Long-term debt | 1.80B | 1.79B | 2.28B | 2.73B | 2.73B | 2.74B | 3.35B | 3.05B |
| Total liabilities | 3,970,000,000.00 | 4,704,000,000.00 | 4,754,000,000.00 | 5,316,000,000.00 | 5,227,000,000.00 | 4,918,000,000.00 | 5,948,000,000.00 | 5,986,000,000.00 |
| Total equity | 4.57B | 4.75B | 4.87B | 5.39B | 5.31B | 5.85B | 5.90B | 6.74B |
| Retained earnings | -336.00M | -18.00M | 81.00M | 348.00M | 324.00M | 782.00M | 750.00M | 1.39B |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 4.21B | 4.25B | 4.59B | 4.62B | 4.76B | 4.69B |
| Cash & ST investments | 1.49B | 1.54B | 1.79B | 1.76B | 1.81B | 1.76B |
| Inventory | 991.00M | 1.01B | 1.03B | 1.06B | 1.09B | 1.12B |
| Total assets | 12.16B | 12.23B | 12.73B | 12.81B | 13.07B | 13.97B |
| Total current liabilities | 2.01B | 1.89B | 2.35B | 2.23B | 2.27B | 2.29B |
| Short-term debt | 146.00M | 59.00M | 304.00M | 304.00M | 304.00M | 304.00M |
| Long-term debt | 3.35B | 3.35B | 3.05B | 3.05B | 3.05B | 3.65B |
| Total liabilities | 6,022,000,000.00 | 5,856,000,000.00 | 5,986,000,000.00 | 5,905,000,000.00 | 5,943,000,000.00 | 6,604,000,000.00 |
| Total equity | 6.14B | 6.37B | 6.74B | 6.91B | 7.12B | 7.36B |
| Retained earnings | 912.00M | 1.10B | 1.39B | 1.48B | 1.69B | 1.91B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.09B | 1.02B | 921.00M | 1.49B | 1.31B | 1.77B | 1.75B | 1.56B |
| Depreciation & amortization | 210.00M | 238.00M | 308.00M | 321.00M | 317.00M | 271.00M | 257.00M | 288.00M |
| Free cash flow | 910.00M | 865.00M | 802.00M | 1.30B | 1.02B | 1.47B | 1.37B | 1.15B |
| Dividends paid | -191.00M | -206.00M | -222.00M | -236.00M | -250.00M | -265.00M | -274.00M | -282.00M |
| Stock buybacks / issuance | -422.00M | -723.00M | -469.00M | -788.00M | -1.14B | -575.00M | -1.15B | -425.00M |
| Ending cash balance | 2.25B | 1.39B | 1.45B | 1.49B | 1.06B | 1.59B | 1.33B | 1.79B |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 221.00M | 362.00M | 545.00M | 268.00M | 277.00M | 519.00M |
| Depreciation & amortization | 73.00M | 72.00M | 71.00M | 67.00M | 67.00M | 66.00M |
| Free cash flow | 107.00M | 259.00M | 452.00M | 175.00M | 201.00M | 439.00M |
| Dividends paid | -70.00M | -71.00M | -70.00M | -72.00M | -72.00M | -72.00M |
| Stock buybacks / issuance | -165.00M | -85.00M | -85.00M | -152.00M | -65.00M | -78.00M |
| Ending cash balance | 1.49B | 1.54B | 1.79B | 1.76B | 1.81B | 1.76B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.72 | 23.00 | 14.95 | 23.58 | 23.45 | 22.24 | 21.95 | 20.62 |
| ROA %i | 3.72 | 11.90 | 7.54 | 11.90 | 11.81 | 11.65 | 11.40 | 10.61 |
| ROIC %i | 5.28 | 15.54 | 10.83 | 16.76 | 16.23 | 15.41 | 14.54 | 13.91 |
| 5-year avg ROE %i | 10.33 | 12.85 | 14.15 | 16.66 | 18.34 | 21.44 | 21.24 | 22.37 |
| EBIT margin %i | 20.78 | 19.23 | 17.23 | 22.80 | 23.19 | 20.99 | 24.84 | 22.27 |
| FCF / sales %i | 18.52 | 16.75 | 15.02 | 20.51 | 14.91 | 21.57 | 21.09 | 16.58 |
| Current ratioi | 3.29 | 1.53 | 2.33 | 2.22 | 2.03 | 2.61 | 2.09 | 1.96 |
| Quick ratioi | 2.58 | 1.11 | 1.69 | 1.61 | 1.32 | 1.80 | 1.40 | 1.40 |
| Debt / assetsi | 21.06 | 25.47 | 24.50 | 25.49 | 26.29 | 25.41 | 28.62 | 26.35 |
| LT debt / equityi | 39.39 | 37.72 | 46.87 | 50.64 | 51.52 | 46.79 | 56.71 | 45.25 |
| Interest coveragei | 13.61 | 13.42 | 11.79 | 17.79 | 18.90 | 15.09 | 16.84 | 13.81 |
| Revenue CAGR (3Y) %i | 6.76 | 7.11 | 6.08 | 8.74 | 9.87 | 8.57 | 1.00 | 0.48 |
| Net income CAGR (3Y) %i | -7.63 | 32.35 | 1.68 | 56.45 | 5.40 | 19.92 | 2.13 | 1.29 |
| FCF CAGR (3Y) %i | 30.02 | 9.77 | 4.00 | 12.54 | 5.68 | 22.49 | 1.92 | 4.11 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | 18.88 | 19.88 | 20.62 | 19.95 | 21.33 | 20.97 |
| ROA %i | 10.13 | 10.51 | 10.61 | 10.43 | 11.21 | 11.00 |
| ROIC %i | 13.03 | 13.56 | 13.91 | 13.56 | 14.46 | 14.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 22.36 | 22.26 | 22.27 | 21.81 | 23.30 | 23.93 |
| FCF / sales %i | 17.94 | 16.03 | 16.58 | 14.06 | 15.03 | 17.19 |
| Current ratioi | 2.09 | 2.25 | 1.96 | 2.07 | 2.10 | 2.05 |
| Quick ratioi | 1.42 | 1.54 | 1.40 | 1.47 | 1.46 | 1.41 |
| Debt / assetsi | 28.75 | 27.88 | 26.35 | 26.18 | 25.68 | 28.27 |
| LT debt / equityi | 54.58 | 52.59 | 45.25 | 44.15 | 42.84 | 49.50 |
| Interest coveragei | 13.35 | 12.91 | 13.81 | 14.14 | 16.05 | 16.64 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Quote time 2026-11-20 20:01:22 · For reference only, not investment advice and not tailored to your situation.
Agilent Technologies discussion 0 comments